IMA 970A

Drug Profile

IMA 970A

Alternative Names: Cancer Vaccine - HEPAVAC; Hepatocellular carcinoma vaccine - HapaVaC; HepaVac-101 vaccine; IMA 970 A

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fondazione IRCCS Istituto Nazionale dei Tumori; immatics biotechnologies GmbH; University of Insurbia; University of Tubingen
  • Developer CureVac; immatics biotechnologies GmbH; National Cancer Institute, Naples
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hepatocellular carcinoma

Most Recent Events

  • 18 Sep 2017 Phase-I/II clinical trials in Hepatocellular carcinoma (Second-line therapy or greater, Combination therapy) in Spain, Germany (Intradermal) (NCT03203005)
  • 05 Jul 2017 Fondazione IRCCS Istituto Nazionale dei Tumori (National Cancer Institute, Naples), Immatics Biotechnologies and CureVac plan a first-in-man phase I/II HepaVac-101 trial for Hepatocellular carcinoma (Combination therapy) in Belgium, France, Germany, Italy, Spain and United Kingdom (NCT03203005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top